Huapont subsidiary secures drug certificates for Mometasone Furoate Cream

Chongqing Huapont Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huapont Life Sciences, has been granted two drug registration certificates by the National Medical Products Administration for Mometasone Furoate Cream. The certificates cover specifications of 0.1% (30g: 30mg) and 0.1% (15g: 15mg). This marks the product's official market approval as a Class 3 chemical drug, deemed to have passed consistency evaluations.

The cream is indicated for the treatment of eczema, neurodermatitis, atopic dermatitis, and pruritus. This approval is expected to enrich Huapont Life Sciences' product pipeline, offering more treatment options for patients with these skin conditions. The company stated it will expedite the initiation of production and sales.

Despite the positive development, Huapont Life Sciences cautioned investors about potential uncertainties in the competitive market environment and advises investors to exercise caution and be aware of investment risks.